Search

Your search keyword '"Keech, Anthony C"' showing total 656 results
Start Over Author "Keech, Anthony C"
656 results on '"Keech, Anthony C"'

3. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review

Author

Ademi, Zanfina, Avis, Suzanne Robyn, Chan, Adam, Contreras, Osvaldo, Coorey, Craig P., Fathieh, Sina, Genetzakis, Elijah, Gholipour, Alireza, Giles, Corey, Hollings, Matthew, Hyun, Karice, Kazi, Samia, Kovacic, Jason C., Larance, Mark, Marathe, Jessica A., Marquina, Clara, Nelson, Adam, Ng, Hooi Hooi, Patrick, Ellis, Peter, Karlheinz, Tran, Andy, Yang, Jean, Zhu, Dantong, Zwack, Clara, Figtree, Gemma A., Vernon, Stephen T., Harmer, Jason A., Gray, Michael P., Arnott, Clare, Bachour, Eric, Barsha, Giannie, Brieger, David, Brown, Alex, Celermajer, David S., Channon, Keith M., Chew, Nicholas W.S., Chong, James J.H., Chow, Clara K., Cistulli, Peter A., Ellinor, Patrick T., Grieve, Stuart M., Guzik, Tomasz J., Hagström, Emil, Jenkins, Alicia, Jennings, Garry, Keech, Anthony C., Kott, Katharine A., Kritharides, Leonard, Mamas, Mamas A., Mehran, Roxana, Meikle, Peter J., Natarajan, Pradeep, Negishi, Kazuaki, O’Sullivan, John, Patel, Sanjay, Psaltis, Peter J., Redfern, Julie, Steg, Philippe G., Sullivan, David R., Sundström, Johan, Vogel, Birgit, Wilson, Andrew, Wong, Dennis, Bhatt, Deepak L., and Nicholls, Stephen J.

Published
2023
Full Text
View/download PDF

4. Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register

Author

Cheng, Feifei, Luk, Andrea O., Wu, Hongjiang, Tam, Claudia H. T., Lim, Cadmon K. P., Fan, Baoqi, Jiang, Guozhi, Carroll, Luke, Yang, Aimin, Lau, Eric S. H., Ng, Alex C. W., Lee, Heung Man, Chow, Elaine, Kong, Alice P. S., Keech, Anthony C., Joglekar, Mugdha V., So, Wing Yee, Hardikar, Anandwardhan A., Chan, Juliana C. N., Jenkins, Alicia J., and Ma, Ronald C. W.

Published
2022
Full Text
View/download PDF

6. High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study)

Author

Ong, Kwok Leung, Hui, Nicholas, Januszewski, Andrzej S, Kaakoush, Nadeem O, Xu, Aimin, Fayyad, Rana, DeMicco, David A, Jenkins, Alicia J, Keech, Anthony C, Waters, David D, Barter, Philip J, and Rye, Kerry-Anne

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Heart Disease, Clinical Trials and Supportive Activities, Cardiovascular, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Anticholesteremic Agents, Atorvastatin, Biomarkers, Cardiovascular Diseases, Coronary Artery Disease, Female, Fibroblast Growth Factors, Humans, Male, Middle Aged, Predictive Value of Tests, Endocrinology & Metabolism, Clinical sciences
Abstract

BackgroundHigher plasma fibroblast growth factor 21 (FGF21) levels predict incident cardiovascular events in type 2 diabetes patients. However, whether FGF21 levels predict cardiovascular events in statin-treated patients in the general population is unknown. We investigated whether FGF21 levels predict major cardiovascular event (MCVE) in the Treating to New Targets (TNT) trial participants.MethodsAfter 8-week run-in on atorvastatin 10 mg/day, 10,001 patients with stable coronary disease in the TNT trial were randomized to 10 mg or 80 mg/day of atorvastatin for a median of 4.9 years. We analyzed data from 1996 patients with plasma FGF21 levels measured at randomization. Among them, 1835 patients had FGF21 measured one-year post-randomization.ResultsHigher ln-transformed FGF21 levels at randomization were associated with higher risk of incident MCVE (adjusted hazards ratio per SD increase = 1.18, P = 0.019). At 1-year post-randomization, FGF21 levels were lower in patients randomized to receive 80 mg versus 10 mg atorvastatin (186.9 versus 207.5 pg/mL respectively, P = 0.006). Higher ln-transformed FGF21 levels at 1-year post-randomization were also associated with higher subsequent risk of MCVEs (adjusted hazards ratio per SD increase = 1.24, P = 0.009). However, changes in FGF21 levels over 1-year were not related to subsequent MCVE risk. FGF21 levels had significant incremental value in net reclassification improvement in MCVE risk prediction.ConclusionsHigher plasma FGF21 levels are associated with higher CVD risk in statin-treated high-risk patients. Higher dose atorvastatin is associated with a reduction in FGF21 levels. FGF21 provides incremental value in CVD risk prediction in statin-treated patients.

Published
2019

9. Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision

Author

Lu, Jean C., Vogrin, Sara, McAuley, Sybil A., Lee, Melissa H., Paldus, Barbora, Bach, Leon A., Burt, Morton G., Clarke, Philip M., Cohen, Neale D., Colman, Peter G., de Bock, Martin I., Jane Holmes-Walker, D., Jenkins, Alicia J., Kaye, Joey, Keech, Anthony C., Kumareswaran, Kavita, MacIsaac, Richard J., McCallum, Roland W., Roem, Kerryn, Sims, Catriona, Stranks, Stephen N., Trawley, Steven, Ward, Glenn M., Sundararajan, Vijaya, Jones, Timothy W., and O'Neal, David N.

Published
2021
Full Text
View/download PDF

10. Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective

Author

Ademi, Zanfina, Ardill, Justin J, Barnett, Wendy, Bates, Timothy R, Beilin, Lawrence J, Bishop, Warrick, Black, J Andrew, Brown, Alex, Burnett, John R, Bursill, Christina A, Colley, Alison, Clifton, Peter M, Ekinci, Elif I, Figtree, Gemma A, Forge, Brett H, Garton-Smith, Jacquie, Graham, Dorothy F, Hamilton-Craig, Ian, Hamilton-Craig, Christian R, Heal, Clare, Hespe, Charlotte M, Hooper, Amanda J, Howes, Laurence G, Ingles, Jodie, Janus, Edward D, Kangaharan, Nadarajah, Keech, Anthony C, Kirke, Andrew B, Kritharides, Leonard, Kyle, Campbell V, Lacaze, Paul, Li, Stephen CH, Maticevic, Stjepana, McQuillan, Brendan M, Mirzaee, Sam, Mori, Trevor A, Morton, Allison C, Colquhoun, David M, Moullin, Joanna C, Nestel, Paul J, Nowak, Kristen J, O'Brien, Richard C, Pachter, Nicholas, Page, Michael M, Psaltis, Peter J, Radford, Jan, Reid, Nicola J, Robertson, Elizabeth N, Ryan, Jacqueline DM, Sarkies, Mitchell N, Schultz, Carl J, Scott, Russell S, Semsarian, Christopher, Simons, Leon A, Spinks, Catherine, Tonkin, Andrew M, van Bockxmeer, Frank, Waddell-Smith, Kathryn E, Ward, Natalie C, White, Harvey D, Wilson, Andrew M, Winship, Ingrid, Woodward, Ann Marie, Nicholls, Stephen J, Brett, Peter, Elias, Luke, Malan, Wynand, Irvin, John, Lambert, Kirsten, Pedrotti, Annette, Watts, Gerald F., Sullivan, David R., Hare, David L., Kostner, Karam M., Horton, Ari E., Bell, Damon A., Brett, Tom, Trent, Ronald J., Poplawski, Nicola K., Martin, Andrew C., Srinivasan, Shubha, Justo, Robert N., Chow, Clara K., and Pang, Jing

Published
2021
Full Text
View/download PDF

11. Integrated Guidance for Enhancing the Care of Familial Hypercholesterolaemia in Australia

Author

Ademi, Zanfina, Ardill, Justin J., Barnett, Wendy, Bates, Timothy R., Beilin, Lawrence J., Bishop, Warrick, Black, J. Andrew, Brett, Peter, Brown, Alex, Burnett, John R., Bursill, Christina A., Colley, Alison, Clifton, Peter M., Ekinci, Elif I., Elias, Luke, Figtree, Gemma A., Forge, Brett H., Garton-Smith, Jacquie, Graham, Dorothy F., Hamilton-Craig, Ian, Hamilton-Craig, Christian R., Heal, Clare, Hespe, Charlotte M., Hooper, Amanda J., Howes, Laurence G., Ingles, Jodie, Irvin, John, Janus, Edward D., Kangaharan, Nadarajah, Keech, Anthony C., Kirke, Andrew B., Kritharides, Leonard, Kyle, Campbell V., Lacaze, Paul, Lambert, Kirsten, Li, Stephen C.H., Malan, Wynand, Maticevic, Stjepana, McQuillan, Brendan M., Mirzaee, Sam, Mori, Trevor A., Morton, Allison C., Colquhoun, David M., Moullin, Joanna C., Nestel, Paul J., Nowak, Kristen J., O'Brien, Richard C., Pachter, Nicholas, Page, Michael M., Pedrotti, Annette, Psaltis, Peter J., Radford, Jan, Reid, Nicola J., Robertson, Elizabeth N., Ryan, Jacqueline D.M., Sarkies, Mitchell N., Schultz, Carl J., Scott, Russell S., Semsarian, Christopher, Simons, Leon A., Spinks, Catherine, Tonkin, Andrew M., van Bockxmeer, Frank, Waddell-Smith, Kathryn E., Ward, Natalie C., White, Harvey D., Wilson, Andrew M., Winship, Ingrid, Woodward, Ann Marie, Nicholls, Stephen J., Watts, Gerald F., Sullivan, David R., Hare, David L., Kostner, Karam M., Horton, Ari E., Bell, Damon A., Brett, Tom, Trent, Ronald J., Poplawski, Nicola K., Martin, Andrew C., Srinivasan, Shubha, Justo, Robert N., Chow, Clara K., and Pang, Jing

Published
2021
Full Text
View/download PDF

12. Shortened relative leukocyte telomere length is associated with all-cause mortality in type 2 diabetes- analysis from the Hong Kong Diabetes Register

Author

Cheng, Feifei, Luk, Andrea O., Wu, Hongjiang, Lim, Cadmon K.P., Carroll, Luke, Tam, Claudia H.T., Fan, Baoqi, Yang, Aimin, Lau, Eric S.H., Ng, Alex C.W., Lee, Heung Man, Chow, Elaine, Kong, Alice P.S., Keech, Anthony C., Joglekar, Mugdha V., So, Wing Yee, Jenkins, Alicia J., Chan, Juliana C.N., Hardikar, Anandwardhan A., and Ma, Ronald C.W.

Published
2021
Full Text
View/download PDF

14. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Author

Sabatine, Marc S, Giugliano, Robert P, Keech, Anthony C, Honarpour, Narimon, Wiviott, Stephen D, Murphy, Sabina A, Kuder, Julia F, Wang, Huei, Liu, Thomas, Wasserman, Scott M, Sever, Peter S, Pedersen, Terje R, and FOURIER Steering Committee and Investigators

Subjects
FOURIER Steering Committee and Investigators, Humans, Cardiovascular Diseases, Hypercholesterolemia, Antibodies, Monoclonal, Anticholesteremic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Drug Therapy, Combination, Incidence, Least-Squares Analysis, Follow-Up Studies, Double-Blind Method, Aged, Middle Aged, Female, Male, Atherosclerosis, Cholesterol, LDL, Antibodies, Monoclonal, Humanized, Proprotein Convertase 9, Cardiovascular, Clinical Research, Heart Disease - Coronary Heart Disease, Heart Disease, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, General & Internal Medicine, Medical and Health Sciences
Abstract

BackgroundEvolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain.MethodsWe conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years.ResultsAt 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P

Published
2017

19. Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors

Author

Figtree, Gemma A., primary, Vernon, Stephen T., additional, Harmer, Jason A., additional, Gray, Michael P., additional, Arnott, Clare, additional, Bachour, Eric, additional, Barsha, Giannie, additional, Brieger, David, additional, Brown, Alex, additional, Celermajer, David S., additional, Channon, Keith M., additional, Chew, Nicholas W.S., additional, Chong, James J.H., additional, Chow, Clara K., additional, Cistulli, Peter A., additional, Ellinor, Patrick T., additional, Grieve, Stuart M., additional, Guzik, Tomasz J., additional, Hagström, Emil, additional, Jenkins, Alicia, additional, Jennings, Garry, additional, Keech, Anthony C., additional, Kott, Katharine A., additional, Kritharides, Leonard, additional, Mamas, Mamas A., additional, Mehran, Roxana, additional, Meikle, Peter J., additional, Natarajan, Pradeep, additional, Negishi, Kazuaki, additional, O’Sullivan, John, additional, Patel, Sanjay, additional, Psaltis, Peter J., additional, Redfern, Julie, additional, Steg, Philippe G., additional, Sullivan, David R., additional, Sundström, Johan, additional, Vogel, Birgit, additional, Wilson, Andrew, additional, Wong, Dennis, additional, Bhatt, Deepak L., additional, Kovacic, Jason C., additional, Nicholls, Stephen J., additional, Ademi, Zanfina, additional, Avis, Suzanne Robyn, additional, Chan, Adam, additional, Contreras, Osvaldo, additional, Coorey, Craig P., additional, Fathieh, Sina, additional, Genetzakis, Elijah, additional, Gholipour, Alireza, additional, Giles, Corey, additional, Hollings, Matthew, additional, Hyun, Karice, additional, Kazi, Samia, additional, Larance, Mark, additional, Marathe, Jessica A., additional, Marquina, Clara, additional, Nelson, Adam, additional, Ng, Hooi Hooi, additional, Patrick, Ellis, additional, Peter, Karlheinz, additional, Tran, Andy, additional, Yang, Jean, additional, Zhu, Dantong, additional, and Zwack, Clara, additional

Published
2023
Full Text
View/download PDF

21. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Author

Swerdlow, Daniel I, Preiss, David, Kuchenbaecker, Karoline B, Holmes, Michael V, Engmann, Jorgen EL, Shah, Tina, Sofat, Reecha, Stender, Stefan, Johnson, Paul CD, Scott, Robert A, Leusink, Maarten, Verweij, Niek, Sharp, Stephen J, Guo, Yiran, Giambartolomei, Claudia, Chung, Christina, Peasey, Anne, Amuzu, Antoinette, Li, KaWah, Palmen, Jutta, Howard, Philip, Cooper, Jackie A, Drenos, Fotios, Li, Yun R, Lowe, Gordon, Gallacher, John, Stewart, Marlene CW, Tzoulaki, Ioanna, Buxbaum, Sarah G, van der A, Daphne L, Forouhi, Nita G, Onland-Moret, N Charlotte, van der Schouw, Yvonne T, Schnabel, Renate B, Hubacek, Jaroslav A, Kubinova, Ruzena, Baceviciene, Migle, Tamosiunas, Abdonas, Pajak, Andrzej, Topor-Madry, Romanvan, Stepaniak, Urszula, Malyutina, Sofia, Baldassarre, Damiano, Sennblad, Bengt, Tremoli, Elena, de Faire, Ulf, Veglia, Fabrizio, Ford, Ian, Jukema, J Wouter, Westendorp, Rudi GJ, de Borst, Gert Jan, de Jong, Pim A, Algra, Ale, Spiering, Wilko, der Zee, Anke H Maitland-van, Klungel, Olaf H, de Boer, Anthonius, Doevendans, Pieter A, Eaton, Charles B, Robinson, Jennifer G, Duggan, David, DIAGRAM Consortium, MAGIC Consortium, Kjekshus, John, Downs, John R, Gotto, Antonio M, Keech, Anthony C, Marchioli, Roberto, Tognoni, Gianni, Sever, Peter S, Poulter, Neil R, Waters, David D, Pedersen, Terje R, Amarenco, Pierre, Nakamura, Haruo, McMurray, John JV, Lewsey, James D, Chasman, Daniel I, Ridker, Paul M, Maggioni, Aldo P, Tavazzi, Luigi, Ray, Kausik K, Seshasai, Sreenivasa Rao Kondapally, Manson, JoAnn E, Price, Jackie F, Whincup, Peter H, Morris, Richard W, Lawlor, Debbie A, Smith, George Davey, Ben-Shlomo, Yoav, Schreiner, Pamela J, Fornage, Myriam, Siscovick, David S, Cushman, Mary, Kumari, Meena, Wareham, Nick J, Verschuren, WM Monique, Redline, Susan, Patel, Sanjay R, Whittaker, John C, and Hamsten, Anders

Subjects
Epidemiology, Biomedical and Clinical Sciences, Health Sciences, Clinical Trials and Supportive Activities, Clinical Research, Genetics, Nutrition, Diabetes, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Metabolic and endocrine, Aged, Body Mass Index, Body Weight, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Type 2, Female, Genetic Testing, Humans, Hydroxymethylglutaryl CoA Reductases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Polymorphism, Single Nucleotide, Randomized Controlled Trials as Topic, Risk Factors, DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundStatins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.MethodsWe used single nucleotide polymorphisms in the HMGCR gene, rs17238484 (for the main analysis) and rs12916 (for a subsidiary analysis) as proxies for HMGCR inhibition by statins. We examined associations of these variants with plasma lipid, glucose, and insulin concentrations; bodyweight; waist circumference; and prevalent and incident type 2 diabetes. Study-specific effect estimates per copy of each LDL-lowering allele were pooled by meta-analysis. These findings were compared with a meta-analysis of new-onset type 2 diabetes and bodyweight change data from randomised trials of statin drugs. The effects of statins in each randomised trial were assessed using meta-analysis.FindingsData were available for up to 223 463 individuals from 43 genetic studies. Each additional rs17238484-G allele was associated with a mean 0·06 mmol/L (95% CI 0·05-0·07) lower LDL cholesterol and higher body weight (0·30 kg, 0·18-0·43), waist circumference (0·32 cm, 0·16-0·47), plasma insulin concentration (1·62%, 0·53-2·72), and plasma glucose concentration (0·23%, 0·02-0·44). The rs12916 SNP had similar effects on LDL cholesterol, bodyweight, and waist circumference. The rs17238484-G allele seemed to be associated with higher risk of type 2 diabetes (odds ratio [OR] per allele 1·02, 95% CI 1·00-1·05); the rs12916-T allele association was consistent (1·06, 1·03-1·09). In 129 170 individuals in randomised trials, statins lowered LDL cholesterol by 0·92 mmol/L (95% CI 0·18-1·67) at 1-year of follow-up, increased bodyweight by 0·24 kg (95% CI 0·10-0·38 in all trials; 0·33 kg, 95% CI 0·24-0·42 in placebo or standard care controlled trials and -0·15 kg, 95% CI -0·39 to 0·08 in intensive-dose vs moderate-dose trials) at a mean of 4·2 years (range 1·9-6·7) of follow-up, and increased the odds of new-onset type 2 diabetes (OR 1·12, 95% CI 1·06-1·18 in all trials; 1·11, 95% CI 1·03-1·20 in placebo or standard care controlled trials and 1·12, 95% CI 1·04-1·22 in intensive-dose vs moderate dose trials).InterpretationThe increased risk of type 2 diabetes noted with statins is at least partially explained by HMGCR inhibition.FundingThe funding sources are cited at the end of the paper.

Published
2015

24. No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy.

Author

Rao, Ben, Januszewski, Andrzej S., Brazionis, Laima, O'Connell, Rachel, Aryal, Nanda, Shimmin, Georgia, O'Day, Justin, Mitchell, Paul, Colman, Peter G., Keech, Anthony C., and Jenkins, Alicia J

Subjects
DISEASE progression, TYPE 2 diabetes, RISK assessment, SOCIAL classes, DESCRIPTIVE statistics, DIABETIC retinopathy, DATA analysis software, EDUCATIONAL attainment, DISEASE risk factors, DISEASE complications
Abstract

In 6002 Australian adults with type 2 diabetes and a median 5‐year follow‐up in the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) trial, baseline socioeconomic status (SES) and self‐reported education level were not related to development of on‐trial sight‐threatening diabetic retinopathy. Similarly, in a retinal photography substudy (n = 549), two‐step diabetic retinopathy progression was not related to SES or education. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease

Author

Marston, Nicholas A., Patel, Parth N., Kamanu, Frederick K., Nordio, Francesco, Melloni, Giorgio M., Roselli, Carolina, Gurmu, Yared, Weng, Lu-Chen, Bonaca, Marc P., Giugliano, Robert P., Scirica, Benjamin M., O’Donoghue, Michelle L., Cannon, Christopher P., Anderson, Christopher D., Bhatt, Deepak L., Gabriel Steg, Philippe, Cohen, Marc, Storey, Robert F., Sever, Peter, Keech, Anthony C., Raz, Itamar, Mosenzon, Ofri, Antman, Elliott M., Braunwald, Eugene, Ellinor, Patrick T., Lubitz, Steven A., Sabatine, Marc S., and Ruff, Christian T.

Published
2021
Full Text
View/download PDF

31. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

Author

Sabatine, Marc S, Leiter, Lawrence A, Wiviott, Stephen D, Giugliano, Robert P, Deedwania, Prakash, De Ferrari, Gaetano M, Murphy, Sabina A, Kuder, Julia F, Gouni-Berthold, Ioanna, Lewis, Basil S, Handelsman, Yehuda, Pineda, Armando Lira, Honarpour, Narimon, Keech, Anthony C, Sever, Peter S, and Pedersen, Terje R

Published
2017
Full Text
View/download PDF

32. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Author

Giugliano, Robert P, Pedersen, Terje R, Park, Jeong-Gun, De Ferrari, Gaetano M, Gaciong, Zbigniew A, Ceska, Richard, Toth, Kalman, Gouni-Berthold, Ioanna, Lopez-Miranda, Jose, Schiele, François, Mach, François, Ott, Brian R, Kanevsky, Estella, Pineda, Armando Lira, Somaratne, Ransi, Wasserman, Scott M, Keech, Anthony C, Sever, Peter S, and Sabatine, Marc S

Published
2017
Full Text
View/download PDF

36. Abstract 13702: A Novel Genetic Risk Score Predicts Ischemic Stroke in Patients With Cardiometabolic Disease

Author

Patel, Parth N, Marston, Nicholas A, Kamanu, Frederick K, Weng, Lu Chen, Bonaca, Marc P, Giugliano, Robert P, Scirica, Benjamin M, OʼDonoghue, Michelle L, Cannon, Christopher P, ANDERSON, Christopher D, Bhatt, Deepak L, Steg, Philippe G, Cohen, Marc, Storey, Robert F, Sever, Peter S, Keech, Anthony C, RAZ, Itamar, Mosenzon, ofri, Braunwald, Eugene, Ellinor, Patrick T, Lubitz, Steven A, Sabatine, Marc S, and Ruff, Christian T

Published
2020
Full Text
View/download PDF

40. Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Author

Sheu, Angela, primary, O’Connell, Rachel L., additional, Jenkins, Alicia J., additional, Tran, Thach, additional, Drury, Paul L., additional, Sullivan, David R., additional, Li, LiPing, additional, Colman, Peter, additional, O’Brien, Richard, additional, Kesäniemi, Y. Antero, additional, Center, Jacqueline R., additional, White, Christopher P., additional, and Keech, Anthony C., additional

Published
2023
Full Text
View/download PDF

41. Optimized plasma sample preparation and LC‐MS analysis to support large‐scale proteomic analysis of clinical trial specimens: Application to the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial

Author

O'Rourke, Matthew B., primary, Januszewski, Andrzej S., additional, Sullivan, David R., additional, Lengyel, Imre, additional, Stewart, Alan J., additional, Arya, Swati, additional, Ma, Ronald, additional, Galande, Sanjeev, additional, Hardikar, Anandwardhan A., additional, Joglekar, Mugdha V., additional, Keech, Anthony C., additional, Jenkins, Alicia J., additional, and Molloy, Mark P., additional

Published
2023
Full Text
View/download PDF

42. REDUCTION IN TOTAL CARDIOVASCULAR EVENTS WITH THE PCSK9 INHIBITOR EVOLOCUMAB IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE COMBINED FOURIER AND FOURIER OPEN-LABEL EXTENSION (OLE) STUDIES

Author

Murphy, Sabina, primary, O'Donoghue, Michelle L., additional, Wiviott, Stephen, additional, Atar, Dan, additional, Keech, Anthony C., additional, Kuder, Julia, additional, Im, KyungAh, additional, Flores-Arredondo, Jose, additional, Antonio, J., additional, Lopez, G., additional, Elliott, Mary, additional, Wang, Bei, additional, Monsalvo, Maria Laura, additional, Abbasi, Siddique A., additional, Giugliano, Robert P., additional, and Sabatine, Marc Steven, additional

Published
2023
Full Text
View/download PDF

43. Corrigendum to “Retinopathy risk calculators in the prediction of sight-threatening diabetic retinopathy in type 2 diabetes: A FIELD substudy” [Diab. Res. Clin. Pract. 186 (2022) 109835]

Author

Rao, Benjamin N., primary, Quinn, Nicola, additional, Januszewski, Andrzej S., additional, Peto, Tunde, additional, Brazionis, Laima, additional, Aryal, Nanda, additional, O'Connell, Rachel L., additional, Li, Liping, additional, Summanen, Paula, additional, Scott, Russell, additional, O'Day, Justin, additional, Keech, Anthony C., additional, and Jenkins, Alicia J., additional

Published
2023
Full Text
View/download PDF

44. Guideline‐based audit of the hospital management of heart failure with reduced ejection fraction.

Author

Drak, Douglas, Fulcher, Jordan, Kilian, Jens, Chong, James J. H., Grover, Rominder, Sindone, Andrew P., Adams, Mark, Lattimore, Jo‐Dee, and Keech, Anthony C.

Subjects
AUDITING, VENTRICULAR ejection fraction, ACE inhibitors, RETROSPECTIVE studies, MEDICAL protocols, ADRENERGIC beta blockers, TREATMENT effectiveness, HOSPITAL mortality, HOSPITAL care, DESCRIPTIVE statistics, RESEARCH funding, ANGIOTENSIN receptors, HEART failure, CHEMICAL inhibitors
Abstract

Background: Heart failure is a major burden in Australia in terms of morbidity, mortality and healthcare expenditure. Multiple evidence‐based therapies are recommended for heart failure with reduced ejection fraction (HFrEF), but data on physician adherence to therapy guidelines are limited. Aim: To compare use of HFrEF therapies against current evidence‐based guidelines in an Australian hospital inpatient population. Methods: A retrospective review of patients admitted with a principal diagnosis of HFrEF across six metropolitan hospitals in Sydney, Australia, between January 2015 and June 2016. Use of medical and device therapies was compared with guideline recommendations using individual patient indications/contraindications. Readmission and mortality data were collected for a 1‐year period following the admission. Results: Of the 1028 HFrEF patients identified, 39 were being managed with palliative intent, leaving 989 patients for the primary analysis. Use of beta‐blockers (87.7% actual use/93.6% recommended use) and diuretics (88.4%/99.3%) was high among eligible patients. There were large evidence‐practice gaps for angiotensin‐converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB; 66.4%/89.0%) and aldosterone antagonists (41.0%/77.1%). In absolute terms, use of these therapies each increased by over 11% from admission. Ivabradine (11.5%/21.2%), automated internal cardiac defibrillators (29.5%/66.1%) and cardiac resynchronisation therapy (13.1%/28.7%) were used in a minority of eligible patients. Over the 1‐year follow‐up period, the mortality rate was 14.8%, and 44.2% of patients were readmitted to hospital at least once. Conclusion: Hospitalisation is a key mechanism for initiation of HFrEF therapies. The large evidence‐practice gaps for ACEI/ARB and aldosterone antagonists represent potential avenues for improved HFrEF management. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

Author

Williams, Kathryn H., Sullivan, David R., Nicholson, Geoffrey C., George, Jacob, Jenkins, Alicia J., Januszewski, Andrzej S., Gebski, Val J., Manning, Patrick, Tan, Yong Mong, Donoghoe, Mark W., Ehnholm, Christian, Young, Simon, O'Brien, Richard, Buizen, Luke, Twigg, Stephen M., and Keech, Anthony C.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results